The Risks and Benefits of AI Protein Design

Learn about AI protein design, machine learning and cancer care, and pharmaceuticals, with CEO and Co-Founder of Exazyme, Ingmar Schuster who uses AI to design proteins. He speaks with @JonKrohnLearns about their wider applications in pharmaceuticals and chemistry, how Kernel methods make the design of synthetic biological catalysts more efficient, and when to use shallow machine learning over deep learning.

You can watch the full interview, “739: AI is Eating Biology and Chemistry — with Dr. Ingmar Schuster” here: https://www.superdatascience.com/739

applications benefits benefits of ai cancer ceo chemistry co-founder design founder kernel learn machine machine learning pharmaceuticals protein proteins risks synthetic